Research programme: sapphyrin-derived apoptosis inducers - Pharmacyclics

Drug Profile

Research programme: sapphyrin-derived apoptosis inducers - Pharmacyclics

Alternative Names: PCI-2000; PCI-2022; PCI-2050; PCI-2051; PCI-2052; PCI-2053

Latest Information Update: 16 Oct 2009

Price : $50

At a glance

  • Originator Pharmacyclics
  • Class Porphyrins
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 19 Oct 2004 Data presented at the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2004) have been added to the Cancer pharmacodynamics section
  • 20 Apr 2004 Data presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR-2004) have been added to the pharmacokinetics and Cancer pharmacodynamics sections
  • 17 Dec 2003 Preclinical trials in Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top